Transjugular intrahepatic portosystemic shunt combined with esophagogastric variceal embolization in the treatment of a large gastrorenal shunt

Table 1 Characteristics of the 81 patients treated with transjugular intrahepatic portosystemic shunt + stomach and esophageal variceal embolization

No. of patients	81 (%)
Men	63 (77.8)
Female	9 (22.2)
Age (yr)
Mean ± SD	50.9 ± 10.9
Range	25-76
Cause of liver disease	n (%)
Viral	61 (75.4)
Alcoholic	7 (8.7)
Viral and alcoholic	1 (1.2)
Primary biliary cirrhosis	4 (4.9)
Autoimmune hepatitis	1 (1.2)
Cryptogenic	7 (8.6)
Child-Pugh class	n (%)
A	15 (18.5)
B	47 (58.0)
C	19 (23.5)
Endoscopic findings
IGV1	25 (30.9)
GOV1	10 (12.3)
GOV2	46 (56.8)
Pre-PPG (mmHg)
Mean ± SD	38.0 ± 6.4
Range	26.0-48.0
Follow-up (mo)
Mean ± SD	7.87 ± 5.57
Range	1-18

PPG: Portosystemic pressure gradient.

Table 2 Comparison of main biochemical data and portosystemic pressure gradient before and after the transjugular intrahepatic portosystemic shunt + stomach and esophageal variceal embolization

	Before TIPS	After TIPS	P
Albumin (mg/dL)	32.24 ± 5.88	33.90 ± 7.26	0.199
ALT (u/L)	30.00 ± 17.51	30.85 ± 20.60	0.806
AST (u/L)	38.00 ± 25.95	41.88 ± 24.03	0.318
Bilirubin (mg/dL)	1.41 ± 0.76	1.45 ± 0.65	0.561
PT (%)	52 ± 14	51 ± 15	0.903
Creatinine (mg/dL)	1 ± 0.3	1 ± 0.4	0.58
Child-Pugh score	6.91 ± 1.44	6.79 ± 1.34	0.563
PPG (mmHg)	38.0 ± 6.4	28.2 ± 6.5	< 0.001

PPG: Portosystemic pressure gradient; TIPS: Transjugular intrahepatic portosystemic shunt; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PT: Prothrombin time.